165 related articles for article (PubMed ID: 25175909)
1. ERG and CHD1 heterogeneity in prostate cancer: use of confocal microscopy in assessment of microscopic foci.
Tereshchenko IV; Zhong H; Chekmareva MA; Kane-Goldsmith N; Santanam U; Petrosky W; Stein MN; Ganesan S; Singer EA; Moore D; Tischfield JA; DiPaola RS
Prostate; 2014 Nov; 74(15):1551-9. PubMed ID: 25175909
[TBL] [Abstract][Full Text] [Related]
2. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer.
Burkhardt L; Fuchs S; Krohn A; Masser S; Mader M; Kluth M; Bachmann F; Huland H; Steuber T; Graefen M; Schlomm T; Minner S; Sauter G; Sirma H; Simon R
Cancer Res; 2013 May; 73(9):2795-805. PubMed ID: 23492366
[TBL] [Abstract][Full Text] [Related]
3. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China.
Dong J; Xiao L; Sheng L; Xu J; Sun ZQ
Asian Pac J Cancer Prev; 2014; 15(7):3099-103. PubMed ID: 24815454
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG
Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163
[TBL] [Abstract][Full Text] [Related]
5. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications.
Barry M; Perner S; Demichelis F; Rubin MA
Urology; 2007 Oct; 70(4):630-3. PubMed ID: 17991527
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort.
Esgueva R; Perner S; J LaFargue C; Scheble V; Stephan C; Lein M; Fritzsche FR; Dietel M; Kristiansen G; Rubin MA
Mod Pathol; 2010 Apr; 23(4):539-46. PubMed ID: 20118910
[TBL] [Abstract][Full Text] [Related]
7. A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.
Qu X; Randhawa G; Friedman C; O'Hara-Larrivee S; Kroeger K; Dumpit R; True L; Vakar-Lopez F; Porter C; Vessella R; Nelson P; Fang M
Cancer Genet; 2013; 206(1-2):1-11. PubMed ID: 23352841
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
[TBL] [Abstract][Full Text] [Related]
9. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.
Mertz KD; Setlur SR; Dhanasekaran SM; Demichelis F; Perner S; Tomlins S; Tchinda J; Laxman B; Vessella RL; Beroukhim R; Lee C; Chinnaiyan AM; Rubin MA
Neoplasia; 2007 Mar; 9(3):200-6. PubMed ID: 17401460
[TBL] [Abstract][Full Text] [Related]
11. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor.
Scheble VJ; Braun M; Beroukhim R; Mermel CH; Ruiz C; Wilbertz T; Stiedl AC; Petersen K; Reischl M; Kuefer R; Schilling D; Fend F; Kristiansen G; Meyerson M; Rubin MA; Bubendorf L; Perner S
Mod Pathol; 2010 Aug; 23(8):1061-7. PubMed ID: 20473283
[TBL] [Abstract][Full Text] [Related]
12. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.
Gopalan A; Leversha MA; Satagopan JM; Zhou Q; Al-Ahmadie HA; Fine SW; Eastham JA; Scardino PT; Scher HI; Tickoo SK; Reuter VE; Gerald WL
Cancer Res; 2009 Feb; 69(4):1400-6. PubMed ID: 19190343
[TBL] [Abstract][Full Text] [Related]
13. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.
Yoshimoto M; Joshua AM; Chilton-Macneill S; Bayani J; Selvarajah S; Evans AJ; Zielenska M; Squire JA
Neoplasia; 2006 Jun; 8(6):465-9. PubMed ID: 16820092
[TBL] [Abstract][Full Text] [Related]
14. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
15. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
[TBL] [Abstract][Full Text] [Related]
16. SPOP mutations in prostate cancer across demographically diverse patient cohorts.
Blattner M; Lee DJ; O'Reilly C; Park K; MacDonald TY; Khani F; Turner KR; Chiu YL; Wild PJ; Dolgalev I; Heguy A; Sboner A; Ramazangolu S; Hieronymus H; Sawyers C; Tewari AK; Moch H; Yoon GS; Known YC; Andrén O; Fall K; Demichelis F; Mosquera JM; Robinson BD; Barbieri CE; Rubin MA
Neoplasia; 2014 Jan; 16(1):14-20. PubMed ID: 24563616
[TBL] [Abstract][Full Text] [Related]
17. Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer.
Braun M; Scheble VJ; Menon R; Scharf G; Wilbertz T; Petersen K; Beschorner C; Reischl M; Kuefer R; Schilling D; Stenzl A; Kristiansen G; Rubin MA; Fend F; Perner S
Histopathology; 2011 Jun; 58(7):1028-36. PubMed ID: 21707704
[TBL] [Abstract][Full Text] [Related]
18. The expression profile and heterogeneity analysis of ERG in 633 consecutive prostate cancers from a single center.
Nie L; Pan X; Zhang M; Yin X; Gong J; Chen X; Xu M; Zhou Q; Chen N
Prostate; 2019 Jun; 79(8):819-825. PubMed ID: 30900303
[TBL] [Abstract][Full Text] [Related]
19. Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer.
Weier C; Haffner MC; Mosbruger T; Esopi DM; Hicks J; Zheng Q; Fedor H; Isaacs WB; De Marzo AM; Nelson WG; Yegnasubramanian S
J Pathol; 2013 Jun; 230(2):174-83. PubMed ID: 23447416
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.
Mehra R; Tomlins SA; Shen R; Nadeem O; Wang L; Wei JT; Pienta KJ; Ghosh D; Rubin MA; Chinnaiyan AM; Shah RB
Mod Pathol; 2007 May; 20(5):538-44. PubMed ID: 17334343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]